Aprea logo 445pt.png
Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)
April 08, 2021 11:15 ET | Aprea Therapeutics
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Screen Shot 2021-01-12 at 7.57.32 PM.png
Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
March 30, 2021 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Apollomics_Logos Final-01.png
Apollomics, Inc. Announces Successful Enrollment of First Patient Into Phase 1 Clinical Trial of APL-106 (Uproleselan Injection) in China
March 04, 2021 07:10 ET | Apollomics, Inc.
FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, China, March 04, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono-...
Logo.png
Acute Myeloid Leukemia Pipeline Assessment 2021 report covers Unmet Needs, Key Opportunities, and Major Players
February 15, 2021 20:00 ET | DelveInsight Business Research LLP
Los Angeles, USA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Acute Myeloid Leukemia Pipeline Assessment 2021 report covers Unmet Needs, Key Opportunities, and Major Players DelveInsight highlights recent...
FINAL Rafafel_Pharma_PHP_LOGO_Updated 05042020_V3 (1).png
UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
December 15, 2020 11:09 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
December 15, 2020 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...
MacroGenics-Logo-(transparent-background).png
MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
December 06, 2020 13:00 ET | MacroGenics, Inc.
31.8% CR/CRh/CRi rate in primary induction failure and early relapsed AML patientsMedian duration of response = 8.13 months ROCKVILLE, MD, Dec. 06, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc....
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020
November 04, 2020 14:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
FINAL Rafafel_Pharma_PHP_LOGO_Updated 05042020_V3 (1).png
Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
October 27, 2020 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Flotetuzumab Publication in Blood Advances
October 15, 2020 16:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, Oct. 15, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...